Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) has been given a consensus recommendation of “Buy” by the ten research firms that are currently covering the firm, MarketBeat Ratings reports. Nine research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $58.78.
A number of research analysts have weighed in on the stock. Wedbush reduced their price target on shares of Xenon Pharmaceuticals from $50.00 to $49.00 and set an “outperform” rating on the stock in a research report on Friday, August 9th. Needham & Company LLC decreased their price target on shares of Xenon Pharmaceuticals from $62.00 to $60.00 and set a “buy” rating for the company in a research report on Monday, August 12th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $65.00 price target on shares of Xenon Pharmaceuticals in a report on Friday, August 9th. William Blair upgraded Xenon Pharmaceuticals to a “strong-buy” rating in a research note on Friday, August 30th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $55.00 target price on shares of Xenon Pharmaceuticals in a research note on Tuesday, September 3rd.
Get Our Latest Research Report on XENE
Institutional Investors Weigh In On Xenon Pharmaceuticals
Xenon Pharmaceuticals Stock Up 3.7 %
Shares of NASDAQ:XENE opened at $40.84 on Friday. The business has a fifty day simple moving average of $40.79 and a 200-day simple moving average of $40.80. Xenon Pharmaceuticals has a 52 week low of $27.99 and a 52 week high of $50.99. The company has a market cap of $3.09 billion, a P/E ratio of -15.07 and a beta of 1.25.
Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) last released its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.05). During the same period last year, the business earned ($0.72) EPS. Sell-side analysts expect that Xenon Pharmaceuticals will post -3.16 earnings per share for the current fiscal year.
About Xenon Pharmaceuticals
Xenon Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders.
Read More
- Five stocks we like better than Xenon Pharmaceuticals
- What is the Dow Jones Industrial Average (DJIA)?
- Symbotic’s Double-Bagger Potential as It Hits a Key Inflection
- P/E Ratio Calculation: How to Assess Stocks
- High Dividend Yields Make These 2 Shipping Stocks Stand Out
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.